Search Results - "PASSALACQUA, R"

Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies by Tomasello, G, Petrelli, F, Ghidini, M, Pezzica, E, Passalacqua, R, Steccanella, F, Turati, L, Sgroi, G, Barni, S

“…Abstract Introduction Major pathologic regression after neoadjuvant therapy is a strong and favorable prognostic factor in several types of cancer (breast,…”
Get full text

Solar Production of Fuels from Water and CO2: Perspectives and Opportunities for a Sustainable Use of Renewable Energy by Passalacqua, R., Centi, G., Perathoner, S.

“…The increasing energy demand, the depletion of fossil fuels and the concern of maintaining clean environment have become the main reasons for a worldwide…”
Get full text

Epidemiological, clinical and pathological characteristics of gastric neoplasms in the province of Cremona: the experience of the first population-based specialized gastric cancer registry in Italy by Donida, B M, Tomasello, G, Ghidini, M, Buffoli, F, Grassi, M, Liguigli, W, Maglietta, G, Pergola, L, Ratti, M, Sabadini, G, Toppo, L, Ungari, M, Passalacqua, R

“…The gastric cancer incidence rate differs widely across geographical areas. In Italy, in the province of Cremona the incidence is high, compared to the…”
Get full text

Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease by Ghidini, M., Hahne, J., Senti, C., Lampis, A., Ratti, M., Pizzo, C., Gobbi, A., Tomasello, G., Passalacqua, R., Valeri, N.

Get full text

Validity and reliability of a Spanish version of the Standardised Assessment of Personality-Abbreviated Scale (SAPAS) for personality disorder screening in community mental health settings by Muñoz-Negro, J.E., Gómez Passalacqua, R., Pumar Alonso, N., Cervilla, J.A.

“…Personality disorders (PDs) are an essential public health problem being frequently underdiagnosed in the mental health (MH) services. This is a…”
Get full text

Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience by Ghidini, M., Donida, B. M., Totaro, L., Ratti, M., Pizzo, C., Benzoni, I., Lomiento, D., Aldighieri, F., Toppo, L., Ranieri, V., Senti, C., Tanzi, G., Martinotti, M., Passalacqua, R., Rovatti, M., Tomasello, G.

“…Background Incidence of gastric cancer (GC) shows different distribution in Italy, with higher incidence in the north and center. We retrospectively analyzed…”
Get full text

Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers by Ratti, M., Valeri, N., Hahne, J.C., Lampis, A., Ghidini, M., Tomasello, G., Tanzi, G., Toppo, L., Pizzo, C., Donida, B., Senti, C., Salati, M., Trombatore, M., Fassan, M., Passalacqua, R.

Get full text

Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy by Procopio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., Chiuri, V.E., Bearz, A., Morelli, F., Ortega, C., Atzori, F., Passalacqua, R., Ratta, R., de Braud, F.G.M., Cappelletti, V., Verzoni, E.

Get full text

Prognostic factors associated with survival and recurrence in resectable gastroesophageal cancer: retrospective analysis of 338 patients operated at the Hospital of Cremona in ten years' time by Ghidini, M., Donida, B.M., Lomiento, D., Ratti, M., Pizzo, C., Aldighieri, F., Toppo, L., Ranieri, V., Senti, C., Tanzi, G., Martinotti, M., Passalacqua, R., Tomasello, G., Rovatti, M.

Get full text

Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC) by Verzoni, E., Cartenì, G., Cortesi, E., Roila, F., Vitale, M.G., Buti, S., Pignata, S., Cognetti, F., Giustini, L., Damiani, A., Turci, D., Sternberg, C.N., Porta, C., Carrozza, F., Tortora, G., Tassinari, D., Passalacqua, R., Pazzola, A., Surico, G., Procopio, G.

Get full text

Treatment and outcome for small bowel adenocarcinoma (SBA): a real life experience of two Italian centres by Occhipinti, M., Botticelli, A., Onesti, C.E., Ghidini, M., Righini, R., Pizzo, C., Milano, A., Tomasello, G., Di Pietro, F.R., Toppo, L., Ratti, M., Passalacqua, R., Marchetti, P., Mazzuca, F.

Get full text

2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) by Passalacqua, R, Montironi, R, Lazzarelli, S, Donini, M, Perrucci, B, Nolè, F, Ceresoli, G.L, Pignata, S, Torricelli, F, Giannatempo, P, Doni, L, Ungari, M, Panni, S, Necchi, A, Betri, E, De Giorgi, U, Sabbatini, R, Rondini, E, Sequino, M, Caminiti, C

Get full text

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice by Barni, S., Lorusso, V., Giordano, M., Sogno, G., Gamucci, T., Santoro, A., Passalacqua, R., Iaffaioli, V., Zilembo, N., Mencoboni, M., Roselli, M., Pappagallo, G., Pronzato, P.

“…Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines…”
Get full text

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT by Di Bartolomeo, M., Pietrantonio, F., Perrone, F., Dotti, K. F., Lampis, A., Bertan, C., Beretta, E., Rimassa, L., Carbone, C., Biondani, P., Passalacqua, R., Pilotti, S., Bajetta, E.

“…There is conflicting evidence on the predictive role of KRAS status when cetuximab is added to oxaliplatin-based regimens. This study investigated the impact…”
Get full text

2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW) by Chau, I, Fuchs, C, Muro, K, Tomasek, J, Van Cutsem, E, Cho, J.Y, Oh, S.C, Safran, H, Bodoky, G, Shimada, Y, Dumitru, F, Passalacqua, R, Ohtsu, A, Hsu, Y, Liepa, A, Chandrawansa, K, Emig, M, Ferry, D, Wilke, H, Al-Batran, S.E

Get full text

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer by Bisagni, G., Musolino, A., Panebianco, M., De Matteis, A., Nuzzo, F., Ardizzoni, A., Gori, S., Gamucci, T., Passalacqua, R., Gnoni, R., Moretti, G., Boni, C.

“…Background Therapeutic approach for patients with metastatic breast cancer (MBC) is still controversial. This study was conducted to assess the efficacy and…”
Get full text

NANO-ENGINEERED MATERIALS FOR H2 PRODUCTION BY WATER PHOTO-ELECTROLYSIS by C. Ampelli, R. Passalacqua, S. Perathoner, G. Centi

Get full text

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg) by Donini, M., Buti, S., Lazzarelli, S., Bozzetti, R., Rivoltini, L., Camisaschi, C., Castelli, C., Bearz, A., Simonelli, C., Lo Re, G., Mattioli, R., Caminiti, C., Passalacqua, R.

“…The aim of this study was to explore the efficacy and toxicities of a combined regimen of bevacizumab plus immunotherapy and chemotherapy (BIC) and the…”
Get full text

Use of mesoporous SBA-15 for nanostructuring titania for photocatalytic applications by Perathoner, S., Lanzafame, P., Passalacqua, R., Centi, G., Schlögl, R., Su, D.S.

“…SBA15–TiO 2 samples prepared by introducing titanium with a grafting method and having TiO 2 loadings below 15 wt.% have been characterized by XRF, XRD, IR,…”
Get full text

7138 POSTER High Rate of Complete Remission (CR) Using Two Sequential, Dose-dense Regimens of Cisplatin, Gemcitabine, and Paclitaxel (CGP) Followed by HD-MVAC in Patients With Metastatic Bladder Cancer (mBC) by Briqhenti, M, Passalacqua, R, Arnaudi, R, Potenzoni, M, Donini, M, Liguigli, W, Poli, R, Lazzarelli, S, Panni, S, Curti, A

Get full text